Eurofins reports continuing strong growth during H1 2008

July 30, 2008

Eurofins’ revenues rose 33% during H1 2008, reaching €287.8m, compared to €216.6m in H1 2007. Q2 2008 revenues were €150.4m (Q2 2007 €113.8m).The increase from prior year figures was due to two factors: firstly Group organic growth for the first half of the year was again over 10% and secondly, the effect of the consolidation of acquisitions made towards the end of 2007. Eurofins confirms its full year revenue objective of €620m.The full first half year results will be published on August 29, 2008

€ million	H1 2008	%	H1 2007	%	Q2 2008	%	Q2 2007	%
Benelux	23.4	8.1	19.2	8.8	12.7	8.4	9.7	8.5
British Isles	25.6	8.9	20.2	9.4	13.7	9.1	11.0	9.7
France	48.9	17.0	42.6	19.7	24.7	16.4	20.6	18.1
Germany	54.3	18.9	47.7	22.0	28.1	18.7	25.3	22.2
North America	36.2	12.6	31.4	14.5	17.3	11.5	16.9	14.9
Scandinavia	65.4	22.7	31.6	14.6	34.6	23.0	16.9	14.9
Other	34.0	11.8	23.9	11.0	19.3	12.8	13.5	11.8
Total	287.8	100.0	216.6	100.0	150.4	100.0	113.8	100.0

Notes

For further information please visit www.eurofins.com or contact:
Investor Relations

Phone: +32-2-769 7383

E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products.

The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.